The company isn’t highly funded like others with Silicon Valley roots — it only raised $1.5 million in venture capital in a seed round. However, GoodRx is on track to generate nearly $100 million in earnings in 2018r, and this growth makes it an attractive buy.
McKesson is reportedly among those interested in acquiring GoodRx, but one of the sources told CNBC it would likely not buy the company. CNBC could not determine the other potential buyers and noted these talks may not result in a sale.
More articles on pharmacy:
Flex Pharma to slash 60% of workforce, consider sale or merger
Here’s AMA’s plan to fight drug shortages
Pharmacist recommended: 30 top OTC health products of 2018
